Stay updated on Nivolumab vs Dacarbazine in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page.

Latest updates to the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.5.2 was added to the page header. Revision: v3.5.0 was removed.SummaryDifference0.0%

- Check14 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the location list. The entry now uses the Italian spelling for the site.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded Naples, Italy, 80131 as a study location and removed Napoli, Italy, 80131.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded Melanoma and related topics (MedlinePlus Genetics) and updated site revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check42 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check49 days agoChange DetectedRemoved the Melanoma condition tag and the MedlinePlus Genetics related topic link from the study page.SummaryDifference0.1%

Stay in the know with updates to Nivolumab vs Dacarbazine in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Dacarbazine in Melanoma Clinical Trial page.